Entyvio Generic Name & Formulations
Vedolizumab 300mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Integrin receptor antagonist.
Single-use vial (20mL)—1
Moderately to severely active ulcerative colitis or Crohn’s disease.
Entyvio Dosage and Administration
Give by IV infusion over 30mins. ≥18yrs: 300mg at Weeks 0, 2, and 6, then every 8 weeks thereafter. Discontinue if no therapeutic benefit by Week 14.
<18yrs: not established.
Entyvio Boxed Warnings
Complete all immunizations according to current guidelines before initiating. Monitor for hypersensitivity reactions during and after infusion. Have epinephrine and antihistamines available. Discontinue if anaphylaxis or other serious infusion-related or hypersensitivity reactions occur. Active, severe infections: not recommended until controlled. Consider withholding if severe infection develops. History of recurring severe infections. Consider tuberculosis screening. Monitor for neurological signs/symptoms (those associated with progressive multifocal leukoencephalopathy [PML]); withhold dosing if suspected; permanently discontinue if confirmed. Discontinue if jaundice or significant liver injury occurs. Pregnancy. Nursing mothers.
Avoid concomitant natalizumab, TNF blockers. Caution with concomitant live vaccines.
Entyvio Adverse Reactions
Nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities; infusion-related or hypersensitivity reactions, PML.
Entyvio Clinical Trials
Register pregnant patients exposed to Entyvio by calling (877) 825-3327.
Entyvio Patient Counseling